Kap-Seok Yang, CEO of Macrogen has announced that the company has signed a strategic License and Supply Agreement with Thermo Fisher Scientific. The agreement, which was recently signed, aims to expand the global market for Capillary Electrophoresis Sequencing (CES) service.
The precision medicine and biotechnology company Macrogen has announced on April 24 that it had signed a supply contract with Exosome Plus on April 19 to become the exclusive buyer of the exosome isolation kits developed by Exosome Plus. The two companies also signed an MOU for the joint development of exosome-based diagnostic and treatment solutions.
The precision medicine and biotechnology company Macrogen (CEO Kap-Seok Yang, www.macrogen.com/en/) announced on April 24 that it had signed a supply contract with Exosome Plus (CEO Jong-Uk Bu, www.exosomeplus.com) on April 19 to become the exclusive buyer of the exosome isolation kits developed by Exosome Plus. The two companies also signed an MOU for the joint development of exosome-based diagnostic and treatment solutions.